Future therapeutic approaches targeting Bcl-2 could reduce desmoplasia in feline epitheliotropic intestinal T-cell lymphomas and, therefore, may contribute to improve prognosis and survival in cats. This evidence concerns the gene BCL2 and enteropathy-associated T-cell lymphoma.